Dyadic International Rebrands as Dyadic Applied BioSolutions
The Pharma Data
JULY 3, 2025
For years, the company was primarily known for licensing its C1 platform for the development of therapeutic biologics and vaccines. However, Dyadic has now sharpened its strategic focus on commercializing non-therapeutic proteins—input molecules that are crucial for downstream manufacturing and production processes in various industries. “We
Let's personalize your content